Grifols to acquire the remaning shares in Biotest for €450m.

Grifols, a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, offered to acquire the remaning shares in Biotest, a global company that supplies plasma protein products and biotherapeutic drugs, for €450m. The delisting agreement contains provisions that Grifols intends to support Biotest in an economically reasonable manner. After the revocation of the stock exchange admission becomes effective, the shares of Biotest will no longer be admitted to trading on a domestic regulated market or a comparable market abroad.